changeable, the lesson here seems to be that it is prudent to investigate both coupling scenarios when attempting and/or encountering difficulties with complex Stille couplings."
The group's advanced archazolid intermediate displayed dose-dependent inhibition of the V-ATPase. "We were quite excited by the V-ATPase assay results obtained for our advanced fragment 1, despite its modest activity (~100 times less potent than the natural product), given the overall structural simplifications relative to the natural product," remarked Professor O'Neil. He continued: "The results make a further case for the C 7 -C 15 region of the natural products being pharmacophorically relevant, and gives us a starting point for future SAR studies. It is also planned to scale up our synthesis of 1 to make this compound more widely available as a new tool for V-ATPase/cancer research."
Despite a computational suggestion that the compound would inhibit the cyclooxygenase (COX) enzyme, no COX inhibitory activity was measured.
"There are a number of interesting questions that have been raised by our COX inhibition results in light of the previous theoretical study," concluded Professor O'Neil. "For instance, does the inactivity of our compound arise from it being too large and/or because it lacks a carboxylic acid terminus? Are other factors such as binding entropies at play? These are all questions that we hope to address through synthesis."
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Synthesis of the C 1 -C 23 Fragment of the Archazolids and Evidence for V-ATPase but not COX Inhibitory Activity
Synlett 2017, 28, 1101-1105 Figure 1 Structure of the archazolid natural products. Glycosylation at either the C 7 or C 15 hydroxyl significantly reduces their V-ATPase inhibitory activity, indicating that these two groups form important interactions with the enzyme. Interestingly, these same hydroxyls are connected by a Z,Z,E-conjugated triene unique to the archazolids. 
